instead of being a single GLP-1 receptor agonist like semaglutide, tirzepatide is a GLP-1/glucose insulinotropic peptide (GIP) dual agonist, which explains the greater weight loss it delivers
It also decreases your stomach acid, which then can lead to problems like heartburn, indigestion after eating food sensitivities, as well as increasing your risk for SIBO or candida
A block diagram of the research is presented in Figure 1
Other endpoints included changes from baseline in waist circumference, abdominal subcutaneous tissue (SAT), trunk fat, and lean body mass
These came with risks, including inconsistent or inaccurate amounts of the active ingredients
Dont cut calories too drastically